Phase I Study of the Combination of Bortezomib and Sorafenib Followed by Decitabine in Patients With Acute Myeloid Leukemia
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2019
Price : $35 *
At a glance
- Drugs Bortezomib (Primary) ; Sorafenib (Primary) ; Decitabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 07 Oct 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 24 Dec 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov. .
- 09 Sep 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2014 to 1 Dec 2014.